2. Signaling Pathways
  3. GPCR/G Protein
  4. CaSR
  5. CaSR Antagonist

CaSR Antagonist

CaSR Antagonists (11):

Cat. No. Product Name Effect Purity
  • HY-10007
    NPS-2143
    		Antagonist 99.33%
    NPS-2143 (SB-262470A), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 (SB-262470A) blocks increases in cytoplasmic Ca2+ concentrations (IC50=43 nM) elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor.
  • HY-14752
    Ronacaleret
    		Antagonist
    Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis.
  • HY-15104
    Ronacaleret hydrochloride
    		Antagonist
    Ronacaleret hydrochloride (SB 751689A) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret hydrochloride (SB 751689A) is used for the study of postmenopausal osteoporosis.
  • HY-103320
    Calhex 231
    		Antagonist
    Calhex 231 is a potent negative allosteric modulator that blocks (IC50 = 0.39 μM) increases in [3H]inositol phosphates elicited by activating the human wild-type CaSR transiently Ca2+-sensing receptor. Calhex 231 can be used in the study of traumatic hemorrhagic shock (THS) and diabetic cardiomyopathy (DCM).
  • HY-10171
    NPS-2143 hydrochloride
    		Antagonist 99.80%
    NPS-2143 hydrochloride (SB-262470A hydrochloride), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 hydrochloride (SB-262470A hydrochloride) blocks increases in cytoplasmic Ca2+ concentrations (IC50=43 nM) elicited by activating the Ca2+ receptor in HEK 293 cells expressing the human Ca2+ receptor.
  • HY-N0546
    Ligustroflavone
    		Antagonist 99.74%
    Ligustroflavone, extracted from Ligustrum lucidum, is a potential candidate as calcium-sensing receptor (CaSR) antagonist. Ligustroflavone exhibits protective effects against diabetic osteoporosis in mice.
  • HY-50713
    Calcium-Sensing Receptor Antagonists I
    		Antagonist 98.95%
    Calcium-Sensing Receptor Antagonists I is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-15105
    SB-423562
    		Antagonist 99.66%
    SB-423562 is a short-acting calcium-sensing receptor (CaR) antagonist. SB-423562 has the potential for osteoporosis research.
  • HY-15106
    SB-423557
    		Antagonist
    SB-423557 is an orally active calcium-sensing receptor (CaR) antagonist (IC50=520 nM), precursor of SB-423562 (IC50=73 nM). SB-423557 is well tolerated in human and increases plasma concentrations of exogenous parathyroid hormone (PTH) and stimulates bone formation.
  • HY-153258
    CaSR antagonist-1
    		Antagonist
    CaSR antagonist-1 is a calcium sensing receptor (CaSR) antagonist with an IC50 value of 50 nM. CaSR antagonist-1 can be used for the research of disorders associated with abnormal bone or mineral homeostasis such as osteoporosis.
  • HY-14401
    Encaleret
    		Antagonist
    Encaleret (CLTX-305) is an orally active CaSR antagonist.